(Q37961181)

26 August 2017

title

Mechanism of HIV antiretroviral drugs progress toward drug resistance (English)

1 reference

26 August 2017

0 references

anti-retroviral agent

0 references

author name string

Palanee Ammaranond

series ordinal

1

1 reference

26 August 2017

Sayompoo Sanguansittianan

series ordinal

2

1 reference

26 August 2017

publication date

27 November 2011

1 reference

Fundamental and Clinical Pharmacology

26 August 2017

published in

1 reference

26 August 2017

volume

26

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

146-161

1 reference

An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

AIDS in haemophiliacs, parenteral drug abusers, and homosexuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Transmission of the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Acquired immunodeficiency syndrome in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

The ribonuclease H activity of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2 is modulated by residue 294 of the small subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Mutagenesis of cysteine 280 of the reverse transcriptase of human immunodeficiency virus type-1: the effects on the ribonuclease H activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Nucleoside-analog resistance mutations in HIV-1 reverse transcriptase and their influence on polymerase fidelity and viral mutation rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

HIV reverse transcriptase: structural interpretation of drug resistant genetic variants from India

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Trapping of a catalytic HIV reverse transcriptase*template:primer complex through a disulfide bond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

5'-aminocarbonyl phosphonates as new zidovudine depot forms: antiviral properties, intracellular transformations, and pharmacokinetic parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)--2',3'-dideoxycytidine (ddC): relevance to HIV-dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Synthesis and anti-HIV activity of beta-D-3'-azido-2',3'-unsaturated nucleosides and beta-D-3'-azido-3'-deoxyribofuranosylnucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Effect of transport inhibitors and additional anti-HIV drugs on the movement of lamivudine (3TC) across the guinea pig brain barriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

21 January 2018

New antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Closing in on HIV drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Mechanism by which phosphonoformic acid resistance mutations restore 3'-azido-3'-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Solution structural dynamics of HIV-1 reverse transcriptase heterodimer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Crystallographic Study of a Novel Subnanomolar Inhibitor Provides Insight on the Binding Interactions of Alkenyldiarylmethanes with Human Immunodeficiency Virus-1 Reverse Transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Genotypic testing for human immunodeficiency virus type 1 drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Discovery and clinical development of HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Effect of polymorphisms on the replicative capacity of protease inhibitor-resistant HIV-1 variants under drug pressure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

HIV integrase, a brief overview from chemistry to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Dipyrimidine-based inhibitors of HIV-1 integrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Structure-based HIV-1 integrase inhibitor design: a future perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Entry coreceptor use and fusion inhibitor T20 sensitivity of dual-tropic R5X4 HIV-1 in primary macrophage infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Novel therapies based on mechanisms of HIV-1 cell entry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

New anti-HIV agents and targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Co-receptor antagonists as HIV-1 entry inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Baseline resistance of primary human immunodeficiency virus type 1 strains to the CXCR4 inhibitor AMD3100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Human immunodeficiency viruses and drug therapy: resistance and implications for antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Investigators of the Quebec Primary Infection Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Antiretroviral-drug resistance among patients recently infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Time trends in primary HIV-1 drug resistance among recently infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Persistence of primary drug resistance among recently HIV-1 infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Identification of a transmission chain of HIV type 1 containing drug resistance-associated mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Rates of transmission of antiretroviral drug resistant strains of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Predicting the unpredictable: transmission of drug-resistant HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Non-adherence to highly active antiretroviral therapy predicts progression to AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Determining the relative efficacy of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Analysis of HIV type 1 protease and reverse transcriptase sequences from Venezuela for drug resistance-associated mutations and subtype classification: a UNAIDS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Changes in the rate of genotypic resistance to antiretroviral drugs in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

The prevalence of antiretroviral drug resistance in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

HIV-1 drug resistance: can we overcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Reduced antiretroviral drug susceptibility among patients with primary HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Molecular and Clinical Epidemiology of CXCR4‐Using HIV‐1 in a Large Population of Antiretroviral‐Naive Individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

Drug-resistant HIV infection among drug-naive patients in Israel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2011.01009.X

10.1111/J.1472-8206.2011.01009.X

21 January 2018

Identifiers

DOI

1 reference

release_cye6cjigenfjribhbx5xuv52em

26 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cye6cjigenfjribhbx5xuv52em

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference